Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Is early intervention worth it?

Edward Yelin1

  • 1Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, California 94143-0920, USA. yelin2@itsa.ucsf.edu

The Journal of Rheumatology. Supplement
|January 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erosion of Traditional Employment: Impact on Health and Economic Well-being.

Journal of occupational and environmental medicine·2025
Same author

Scoping Total Worker Health: An Expanded View of Worker Well-being.

Journal of occupational and environmental medicine·2025
Same author

The impact of alternative arrangements, contingent jobs, and work secured through an app on the well-being of working age adults: Results from the California Work and Health Survey.

American journal of industrial medicine·2024
Same author

Response.

Chest·2022
Same author

Military Service and COPD Risk.

Chest·2022
Same author

The Impact of Asthma and Chronic Obstructive Pulmonary Disease (COPD) on Patient-Reported Outcomes in Systemic Lupus Erythematosus (SLE).

ACR open rheumatology·2021
Same journal

GRAPPA 2019 Research Recipient Awards Report.

The Journal of rheumatology. Supplement·2021
Same journal

GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting.

The Journal of rheumatology. Supplement·2021
Same journal

GRAPPA Patient Research Partner Network: Update to the GRAPPA 2020 Annual Meeting.

The Journal of rheumatology. Supplement·2021
Same journal

Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group.

The Journal of rheumatology. Supplement·2021
Same journal

GRAPPA 2020 Update From the Education Committee.

The Journal of rheumatology. Supplement·2021
Same journal

The Role of Ultrasound in Research and Clinical Practice in Psoriatic Arthritis: Highlights From the GRAPPA Ultrasound Workshop.

The Journal of rheumatology. Supplement·2021
See all related articles

Evaluating the cost-effectiveness of rheumatoid arthritis (RA) treatments is complex due to long-term benefits like reduced surgery and sustained employment. Disconnected financial interests and equitable access pose significant challenges for these expensive interventions.

Area of Science:

  • Rheumatology
  • Health Economics
  • Public Health Policy

Background:

  • Rheumatoid arthritis (RA) is a common inflammatory rheumatic disease with significant associated costs, primarily from hospitalizations (joint replacement) and work loss.
  • Expensive interventions, such as biological agents, must demonstrate value by reducing joint replacement surgeries and enabling sustained employment for individuals with RA.
  • The time lag between treatment expenditure and long-term outcomes (surgery avoidance, maintained employment) complicates cost-effectiveness assessments.

Purpose of the Study:

  • To analyze the complexities in determining the cost-effectiveness of interventions for rheumatoid arthritis (RA).
  • To explore the computational and political challenges in valuing long-term health benefits.
  • To examine the ethical considerations surrounding the financing and access to advanced RA treatments.

Related Experiment Videos

Main Methods:

  • Analysis of cost-benefit separation in time for RA interventions.
  • Examination of stakeholder alignment in healthcare expenditure and benefit realization.
  • Review of financing mechanisms and equity in access to RA treatments.

Main Results:

  • Cost-effectiveness is difficult to assess when benefits like avoided surgeries and maintained employment occur years after treatment.
  • Discrepancies exist between entities funding interventions (e.g., health insurance) and those benefiting from outcomes (e.g., disability insurance).
  • Ethical concerns arise from financing advanced RA treatments through regressive taxes while access is limited by restrictive insurance plans.

Conclusions:

  • The "worth" of early RA interventions hinges on the time lag between costs and benefits, stakeholder alignment, and equitable financing.
  • Addressing computational challenges in valuing future benefits and political/ethical issues is crucial for fair assessment of RA treatment expenditures.
  • Policy and economic models must account for long-term impacts and equitable access to ensure value and fairness in RA care.